Overview
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
Status:
Terminated
Terminated
Trial end date:
2009-09-01
2009-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alcon ResearchTreatments:
Anecortave
Hydrocortisone
Criteria
Inclusion Criteria:- Clinical diagnosis of Open-Angle Glaucoma or Ocular Hypertension for at least 6
months;
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Prior angle surgery in the study eye, severe visual field loss in either eye;
- Other protocol-defined exclusion criteria may apply.